RecruitingNCT06006819

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease


Sponsor

Cheng-Hsin General Hospital

Enrollment

155 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.


Eligibility

Min Age: 20 YearsMax Age: 90 Years

Inclusion Criteria1

  • hospitalized for acute heart failure

Exclusion Criteria1

  • initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

Locations(1)

Cheng Hsin General Hospital

Taipei, Baitou District, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06006819


Related Trials